KYLE WARD: Open Payments
NPI 1124548995 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$695 in 35 payments from 10 companies in 2025. Trend: 2023 $378 · 2024 $578 · 2025 $695
Food & beverage: $695
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $167 |
| Janssen Pharmaceuticals, Inc | 5 | $128 |
| E.R. Squibb & Sons, L.L.C. | 5 | $93 |
| Teva Pharmaceuticals USA, Inc. | 5 | $85 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Lundbeck LLC | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $21 |
| Tris Pharma Inc | 1 | $19 |
Products named: INGREZZA, COBENFY, REXULTI, INVEGA SUSTENNA, SPRAVATO, UZEDY, AUSTEDO XR, FANAPT.
Industry payments across MD — which companies pay providers there.
